This study is looking at a combination of two drugs, teclistamab and daratumumab, to see if they are safe and effective for people with AL amyloidosis. AL amyloidosis is a condition where abnormal proteins called amyloid build up in organs. Teclistamab works by targeting specific cells (T-cells and plasma cells), and daratumumab targets a protein (CD38) on myeloma cells. The main goal is to see if this combination can lead to a complete blood response (Hematologic Complete Response) within 6 months. You might be able to join if you are 18 years or older. The study aims to reduce harmful proteins in your blood to prevent organ damage, improve organ function, and help you live longer.

Study design

This is an interventional study planning to enroll 25 participants. It is designed to assess the effectiveness and safety of the teclistamab-daratumumab combination.

What's involved

The study treatment is divided into cycles, with each cycle lasting 28 days. The expected duration of study treatment is 6 months.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Hematologic Complete Response, is measured at 6 months from treatment initiation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.